lundi 31 juillet 2017

Onco Actu du 31 juillet 2017

2.3 Etiologie - OGM

Most anti-GMO papers contain serious flaws [The Logic of Science]

3.1 Tabac

FDA announces comprehensive regulatory plan to shift trajectory of tobacco-related disease, death [FDA]

FDA Announces a Major Shake Up in Tobacco Regulatory Policy [FDA Law Blog]

FDA announces plans to slash nicotine levels in cigarettes [STAT]

Tobacco's Teflon Gets Tested [Bloomberg]

Tobacco Shares Plunge After FDA Proposes Cut to Cigarette Nicotine [Bloomberg]

3.1.1 Tabac - e-cigs

F.D.A. Delays Rules That Would Have Limited E-Cigarettes on Market [NY Times]

5. Traitements

IMRT: bending radiotherapy beams to spare healthy cells [Cancer Research UK]

5.10 Traitements - Essais

Research into clinical trial transparency shows huge variation in standards [Pharmafile]

5.12 Immunothérapies

Cancer immunotherapy drugs like Keytruda and Opdivo hold hope for some, but there’s still a way to go [The Conversation]

A humbling setback for an immune-revving cancer therapy underscores the many questions facing the field [STAT]

Calling time on the immunotherapy gold rush [The Lancet Oncology]

5.12.5 Immunothérapies - Pharma

AstraZeneca drug gets breakthrough status in early lung cancer [Reuters]

Imfinzi granted Breakthrough Therapy Designation by US FDA for patients with locally-advanced unresectable non-small cell lung cancer [AstraZeneca]

CheckMate-227: Bristol-Myers Squibb has a MYSTIC problem [EndPoints]

5.2 Pharma

GSK Rearranges, Once More [In the Pipeline]

5.2.1 Pharma - Partenariats

Shooting for the moon: The National Cancer Institute’s Formulary [Pharmafile]

5.2.3 Pharma - économie

Still reeling from cyberattack, Merck warns some drug supplies may be delayed [FiercePharma]

Soon-Shiong’s NantCell in $356M deal for underperforming CytRx cancer drug [FierceBiotech]

Biotech billionaire Soon-Shiong picks up rights to CytRx’s troubled cancer drug [EndPoints]

Merck admits cyberattack is having an impact on research, manufacturing — we’re just not sure how big [EndPoints]

Merck profit tops estimates as Keytruda sales surge [Reuters]

5.3 Traitements - FDA, EMA, NICE...

EMA Lays out Plans for Companion Diagnostic Guideline [RAPS]

Concept paper on development and lifecycle of personalised medicines and companion diagnostics [EMA]

5.4 Traitements - Economie

US Drug Prices And R&D, Take 2: A Reply To Grabowski And Manning, And To Light [Health Affairs blog]

6. Lutte contre les cancers

Don't run biomedical science as a business [Nature]

6.11 Patients

In debt with cancer: Is your bank listening? [BBC News]

6.5 Médecines alternatives

These People Are Making Money Off A Bogus Cancer Cure That Doctors Say Could Poison You [BuzzFeed]

6.7 DMP, Big Data & applis

Two Methods to De-identify Large Patient Datasets Greatly Reduced the Risk of Re-identification [AACR]